Daily low-dose aspirin therapy is recommended for which group of diabetes patients?

Daily low-dose aspirin therapy is specifically recommended for patients with diabetes who also have a history of atherosclerotic cardiovascular disease (ASCVD). This recommendation is based on evidence showing that individuals with diabetes have an increased risk of cardiovascular events, and those with a history of ASCVD are at an even higher risk. Aspirin has antiplatelet properties, which can help in the prevention of subsequent cardiovascular events such as heart attacks and strokes.

Individuals with diabetes, particularly those who have additional risk factors such as a previous history of cardiovascular disease, can benefit significantly from the protective effects of low-dose aspirin. This tailored approach focuses on those who are most likely to experience cardiovascular complications, aligning treatment with individual risk profiles.

Other groups, such as those with only type 1 diabetes or all diabetes patients without the specified cardiovascular risks, may not have the same level of benefit from aspirin therapy. Moreover, there are risks associated with aspirin use, including gastrointestinal bleeding, that necessitate a careful consideration of who should receive this therapy. Therefore, the recommendation is selective and designed to optimize patient outcomes based on individual risk assessments.